NIAID Banner Logo Image

HIV Drugs in Development


Drug ClassCompanyDrug NameAlt NameDrug StatusNotesAIDS#
Antibody, Broadly NeutralizingNational Institute of Allergy and Infectious Diseases (NIAID)SAR441236A tri-specific broadly neutralizing antibody against HIVPhase 1Not Yet Recruiting 
Antibody, MonoclonalNational Institutes of Health Clinical Center (CC)Pembrolizumab Phase 1Recruiting 
Antibody, MonoclonalOttawa Hospital Research Institute Entyvio™Vedolizumab; A humanized monoclonal antibodyPhase 2Recruiting 
Antibody, MonoclonalSt George's, University of LondonP2G12 Phase 1Not Yet Recruiting 578224
Antibody, MonoclonalNational Institute of Allergy and Infectious Diseases (NIAID)CemiplimabAnti-PD-1 AntibodyPhase 1/2Not Yet Recruiting 
Antibody, MonoclonalUnited BioPharmaUB-421Monoclonal antibody; mAb dB4C7Phase 3Not Yet Recruiting 
Antibody, MonoclonalNational Institute of Allergy and Infectious Diseases (NIAID)VRC07-523LSVRC07-523-LS; VRC-HIVMAB075-00-ABPhase 1/2Recruiting 599294
CRM1 InhibitorKaryopharm TherapeuticsVerdinexorKPT335Phase 1Completed 
Capsid InhibitorGilead SciencesGS-6207 Phase 1Recruiting 
CombinationSt. Stephens AIDS TrustTivicay™ and Rezolsta™Dolutegravir and Darunavir and CobicistatPhase 1Completed 
CombinationMylanSynfi™; Telura™TLE400; Efavirenz, Lamivudine and Tenofovir Disoproxil FumarateFDA Approved (March 2018)  
Combination Janssen Pharmaceuticals, Inc.Symtuza™Darunavir and Emtricitabine and Cobicistat and Tenofovir alafenamideFDA Approved (July 2018)  
CombinationMerckDelstrigo™MK-1439A; Doravirine and Lamivudine and Tenofovir disoproxil fumarateFDA Approved (August 2018)  
CombinationGlaxoSmithKlineGSK1349572; Tivicay™ and Epivir™Dolutegravir and LamivudineNew Drug Application (NDA) Submitted (October 2018)  
Entry and/or Fusion InhibitorSangamo BioSciencesSB-728-T Phase 1/2Completed 
Entry and/or Fusion InhibitorSangamo BioSciencesSB-728-HSCSB-728mR-HSPCPhase 1Recruiting 
Entry and/or Fusion InhibitorCytoDyn, Inc.; Progenics PharmaceuticalsPRO-140PA14Phase 2/3Ongoing 088103
Entry and/or Fusion InhibitorPfizerPF-00232798 Phase 2Completed 582838
Entry and/or Fusion InhibitorIncyte CorporationINCB-009471INCB-9471Phase 2Completed 503495
Entry and/or Fusion InhibitorBristol-Myers SquibbFostemsavirBMS-663068; prodrug of BMS-626529Phase 3Ongoing 
Entry and/or Fusion InhibitorTobira TherapeuticsCenicrivirocTBR-652; TAK-652Phase 2Completed 224423
Entry and/or Fusion InhibitorGenzyme CorporationAMD-070AMD-11070Phase 1/2Completed 495149
Entry and/or Fusion InhibitorRapid PharmaceuticalsAdaptavirRAP101; monomeric d-Ala-peptide T-amide (mDAPTA)Phase 2Unknown 052004
Entry and/or Fusion InhibitorMerck (Schering-Plough)VicrivirocSCH-417690, SCH-D, VCVDevelopment Discontinued  210504
HIV Latency Reversing AgentThe Peter Doherty Institute for Infection and ImmunityAntabuse™ and Zolinza™Disulfiram and VorinostatPhase 1/2 Suspended 
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorNovartisPanobinostat  Phase 1/2Recruiting 580714
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorAbbott LabsEpival™; Depakote™Valproic acid, Divalproex sodium, Valproate(VPA)Phase 2Unknown 057177
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorMerckZolinza™Vorinostat; MK-0683, Suberoylanilide Hydroxamic Acid (SAHA), CCRIS 8456Phase 1/2Completed 186714
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorErasmus Medical CenterValproic Acid Phase 1/2Recruiting 057177
HIV Latency Reversing Agent; Histone Deacetylase (HDAC) InhibitorAarhus University HospitalRomidepsin Phase 2Completed 565088
HIV Latency-Reversing Agent; Toll-Like Receptor 3 (TLR-3) AgonistOncovir, IncHiltonol™Poly-ICLCPhase 1/2Completed 187148
ImmunomodulatorGlaxoSmithKlineTucaresol589CDevelopment Discontinued  029800
ImmunomodulatorMerckPegasys™PEG IFN alpha-2aPhase 3Completed 
ImmunomodulatorUniversity of AarhusLefitolimodMGN-1703Phase 1/2Completed 
ImmunomodulatorUniversity of MinnesotaIL-15Interleukin 15Phase 1Recruiting 398478
ImmunomodulatorAmgenEnbrel™Etanercept; p75 TNFR-Fc fusion proteinPhase 1Completed 
ImmunomodulatorFred Hutchinson Cancer Research CenterCellCept™; Myfortic™Mycophenolate MofetilPhase 2Recruiting 059828
ImmunomodulatorNational Institute of Allergy and Infectious Diseases (NIAID)Arava™LeflunomidePhase 1Completed 009747
ImmunomodulatorPfizer (Wyeth)Ammonium Trichlorotellurate; OssireneAS-101Phase 1Completed 000042
ImmunomodulatorThe Research Council of NorwayEtoricoxib Phase 2Completed 
Integrase InhibitorGilead SciencesBictegravirBIC; GS-9883Phase 3Recruiting 592431
Integrase InhibitorViiV Healthcare; GlaxoSmithKlineCabotegravirGSK1265744; S-265744 Phase 3Recruiting 598037
Integrase InhibitorViiV Healthcare; GlaxoSmithKlineGSK1247303 Phase 1Terminated 
Integrase InhibitorNational Institute of Allergy and Infectious Diseases (NIAID)Long-acting Injectable Cabotegravir  Phase 1/2Not Yet Recruiting 
Integrase InhibitorBoehringer IngelheimBI-224436 Phase 1Completed 566575
Janus Kinase InhibitorNational Institute of Allergy and Infectious Diseases (NIAID)Ruxolitinib Phase 2Completed 564288
Maturation InhibitorBristol-Myers SquibbBMS-955176GSK3532795Phase 2Completed 
Maturation InhibitorViiV Healthcare; GlaxoSmithKlineGSK2838232 Phase 2Recruiting 
Maturation InhibitorViiV Healthcare; GlaxoSmithKlineGSK3640254 Phase 1/2Not Yet Recruiting 
MicrobicideStarpharmaVivaGel™SPL-7013 gelPhase 1/2Completed 223863
MicrobicideReprotect, Inc.BufferGel™Carbomer 974P, Carbopol 974P, Carbopol polymerPhase 2Completed 180064
MicrobicideGilead SciencesTenofovir gelGS-1278; PMPA gel, Apropovir, TFVPhase 3Completed 021800
MicrobicideProcept/Interneuron/IndevusPro-2000PRO-2000/5Phase 3Completed 032942
MicrobicidePopulation CouncilPC-1005 Phase 1Completed 
MicrobicideGlaxoSmithKlineGSK706769 Phase 1Completed 
MicrobicidePopulation CouncilGriffithsin Gel Phase 1Recruiting 
MicrobicideJohns Hopkins UniversityDuoGelIQP-0528Phase 1Recruiting 104929
MicrobicideInternational Partnership for Microbicides, Inc.DS003 Phase 1Completed 335384
MicrobicideTibotec Pharmaceuticals; Janssen; Johnson & JohnsonDapivirineTMC-120, GEL-02, R147681, DAPPhase 3Completed 105293
MicrobicidePopulation Council Center for Biomedical ResearchCarraguard™Carragaen, Carrageenan gum, Carrageenin, Irish moss extract, PC-515, Sea Algal ExtractPhase 3Completed 000100
MicrobicideUniroyal/Crompton Corp/BiosynUC781ThiocarboxanilidePhase 1Completed 029940
MicrobicideMyrexis, Inc.; Panacos PharmaceuticalsBevirimatBVM, PA-457, MPC-4326, DSB, YK-FH312Phase 2Completed 028530
NNRTIBoehringer IngelheimBILR 355 BS Phase 2Terminated 212773
NNRTIKainos MedicineKM-023 Phase 1Completed 
NNRTIPfizerLersivirineUK453,061Development Discontinued  497274
NNRTIMerckPifeltro™Doravirine; MK-1439FDA Approved (August 2018)  525576
NNRTISt. Stephens AIDS TrustTMC278-LAA long-acting formulation of Janssen's RilpivirinePhase 2Completed 169030
NNRTIViriomVM-1500Elpida, elpivirine, prodrug of VM-1500A, prodrug of elsulfavirinePhase 2/3Completed 
NNRTIViriomVM-1500A (long acting injection) Phase 1Not Yet Recruiting 
NNRTIViiV Healthcare; GlaxoSmithKlineFosdevirineGSK2248761; IDX-899Phase 2Completed 485324
NRTIGilead SciencesTenofovir Alafenamide (Prodrug of tenofovir)GS-7340Phase 3Completed 046774
NRTIPharmasset; Dupont Pharmaceuticals; VionReverset ™Dexelvucitabine; DFC, 5F-D4C, beta D-d4FC, DPC 817, RA 131423, RVTPhase 2Completed 000572
NRTIGlaxo Wellcome; GlaxoSmithKline; Pharmasset, Inc.RacivirRCV; (+/-)FTC, 5-FSddC, LDS-022, PSI 5004Phase 2Completed 005245
NRTIMerckMK-8591EFdAPhase 2Ongoing 343654
NRTIMerckMK-8583 (tenofovir prodrug) Phase 1Recruiting 
NRTIMerckMK-8504Prodrug of tenofovirPhase 1Completed 
NRTIKoronisKP-1461 (Prodrug of KP1212)SN-1461 (Prodrug of SN1212)Phase 2Terminated 293211
NRTIGilead SciencesGS-9131 Phase 2Active, not recruiting 354427
NRTIAchillion Pharmaceuticals; Vion PharmaceuticalsElvucitabineACH-126443; beta-L-Fd4CPhase 2Completed 060327
NRTIChimerixCMX-157Hexadecyloxypropyl ester of Tenofovir, HDP-(R)-PMPAPhase 2Completed 477886
NRTIOncolys BioPharma; Brisol-Myers SquibbCensavudine; (renaming of Festinavir)4'-ethynyl-d4T; BMS-986001; OBP-601Phase 2Terminated 209894
NRTIRFS Pharma; Biochem Pharma; Triangle Pharmaceuticals; Gilead SciencesAmdoxovirDAPDPhase 2Completed 005431
NRTIAvexaApricitabine(-)-Dotc; ATC; AVX-754; BCH-10618; BCH-10619; BCH-10652; SPD-754Development Discontinued  058066
Protease InhibitorConcert PharmaceuticalsC-10297Isotopic Analog of Atazanavir (ATV)Phase 1Completed 
Protease InhibitorConcert PharmaceuticalsC-10299Isotopic Analog of Atazanavir (ATV)Phase 1Completed 
Protease InhibitorTemple UniversityTMB-607PPL-100; MK-8122Phase 1Recruiting 
Protease InhibitorTibotec PharmaceuticalsTMC-310911 Phase 2Completed 483146
Protease InhibitorConcert PharmaceuticalsC-10276Isotopic Analog of Atazanavir (ATV)Phase 1Completed 
Proteasome InhibitorMayo ClinicNinlaro™IxazomibPhase 1/2Recruiting 
Rev InhibitorAbivax S.AABX464 Phase 2Completed 516635
Toll-Like Receptor 7 (TLR-7) AgonistGilead SciencesVesatolimodGS-9620Phase 1Ongoing 574840
UnidentifiedMerckMK-1972 Phase 1Terminated 
UnidentifiedMerckMK-4250 Phase 1Recruiting 

If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: January 2019